SCHEMBL18632526

SCHEMBL18632526

O=c1[nH]nc2ccc(-c3ccccc3-c3cccc(F)c3)cn12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.47
NOTUM Q6P988 2/20 0.42
LTK P29376 2/20 0.41
ALK Q9UM73 2/20 0.41
DYRK1B Q9Y463 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
RET P07949 1/20 0.41
MET P08581 1/20 0.41
GRK5 P34947 1/20 0.41
CDK8 P49336 1/20 0.41
RPS6KA3 P51812 1/20 0.41
MST1R Q04912 1/20 0.41
TYRO3 Q06418 1/20 0.41
DYRK1A Q13627 1/20 0.41
LRRK2 Q5S007 1/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18632534 0.89 SCN5A (0.54) SCN5ANOTUMRXFP1APOBEC3GGRM2
SCHEMBL18632511 0.85 LTK (0.55) SCN5ANOTUMLTKALKDYRK1B
SCHEMBL18632514 0.80 SCN5A (0.50) SCN5ANOTUMLTKALKDYRK1B
SCHEMBL18632537 0.79 SCN5A (0.48) SCN5ANOTUMLTKALKDYRK1B
SCHEMBL18632538 0.78 SCN5A (0.57) SCN5ANOTUMLTKALKDYRK1B
SCHEMBL18632531 0.77 SCN5A (0.47) SCN5ALTKALKDYRK1BCLK4
SCHEMBL18632530 0.77 SCN5A (0.62) SCN5ANOTUMLTKALKDYRK1B
SCHEMBL18632535 0.77 SCN5A (0.62) SCN5ANOTUMLTKALKDYRK1B
SCHEMBL18632513 0.77 SCN5A (0.49) SCN5ANOTUMLTKALKDYRK1B
SCHEMBL18632523 0.76 SCN5A (0.52) SCN5ANOTUMLTKALKDYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
WO-2017046318-A1 TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2017-03-23 WO disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease HOFFMANN LA ROCHE (CH) 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081323-A1 Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease OAT, XDH, MAPT SCN5A 1311/4885NOTUM 541/4885LTK 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.